Monday, July 13th | 21 Tammuz 5780

Subscribe
May 3, 2020 9:11 am

Israeli Biotech Company Starts Clinical Trials of CBD-Steroid Treatment for Virus

avatar by JNS.org

Rabin Medical Center in Petach Tikvah, Israel. Photo: Wikimedia Commons.

JNS.org – The Israel-based biotech company Stero Biotechs has started a small-scale clinical trial at Rabin Medical Center’s Golda Hasharon Campus in Petach Tikvah on the effects of a steroid-Cannabidiol (CBD) treatment on hospitalized COVID-19 patients.

“Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus,” the company said in a press release announcing the clinical trial. “The initial study will evaluate the tolerability, safety and efficacy of the CBD treatment for hospitalized patients with COVID-19 Infections.”

Ten patients will be in the clinical trial; the treatment cycle will be for a few weeks with a follow-up period of the same length. Pending the trial’s success, the company plans to expand to a multi-center clinical trial with an additional 40 hospitalized COVID-19 patients, under FDA clinical trial guidelines and regulations.

“We estimate that our CBD-based treatment can enhance the current treatment of those patients who are suffering life-threatening conditions,” said Stero Biotechs Founder and CEO David Bassa.

Related coverage

July 13, 2020 10:34 am
0

Israel-US BIRD Foundation Invests $8 Million in 10 New Collaborations

CTech - The board of Governors of the Israel-US Binational Industrial Research and Development (BIRD) Foundation approved $8 million in...

“Hospitalized COVID-19 patients are mostly being treated with steroids, and our study is planned to demonstrate the benefit of a combined solution with steroid treatments,” he continued. “We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”

Stero Biotechs, founded in 2017 and headquartered in Israel, is a clinical-stage company that focuses on the research and development of novel CBD-based treatment solutions.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.